Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
The Motley Fool
by newsfeedback@fool.com (Jonathan Ponciano)February 19, 2026
AI-Generated Deep Dive Summary
Connecticut-based investment firm Braidwell made headlines by selling 1,779,953 shares of Xenon Pharmaceuticals (NASDAQ: XENE) in a $74.76 million transaction, as detailed in its February 17, 2026, SEC filing. This sale significantly reduced Braidwell's stake
Verticals
financeinvesting
Originally published on The Motley Fool on 2/19/2026